Abstract
High-quality biobanking within routine health services, through the use of existing health-care practices and infrastructure, with respect to safety and integrity of patients in line with the Swedish Biobank Act, enables large-scale collection of biological material at reasonable costs. Complementing the extensive information on myocardial infarction patients from a national registry gives unique opportunities for research focusing on better understanding of cardiovascular disease occurrence and prognosis, developing of new diagnostic methods, and personalized treatments with greater efficacy and fewer side effects.
Highlights
Already extensive research is being carried out using data from SWEDEHEART (5), which can be escalated by linking biobank data and samples to the registry
There are currently several regional initiatives where blood samples are collected as part of individual research projects in which phenotypic information is obtained from the SWEDEHEART registry
After approval by the Regional Ethical Review Board in Uppsala, the blood sample collection was started on 12 September 2011 at the Department of Cardiology, Uppsala University Hospital, in close collaboration with the Clinical Laboratory, Uppsala Clinical Research Center, and Uppsala Biobank
Summary
ISSN: 0300-9734 (Print) 2000-1967 (Online) Journal homepage: https://www.tandfonline.com/loi/iups.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
